Evidence map›Paper›PMID 29593726›Full record

Observational studyFrontiers in immunology2018

Pretransplant IgA-Anti-Beta 2 Glycoprotein I Antibodies As a Predictor of Early Graft Thrombosis after Renal Transplantation in the Clinical Practice: A Multicenter and Prospective Study.

Jose M Morales, Manuel Serrano, Jose Angel Martinez-Flores, Fracisco Javier Gainza, Roberto Marcen, Manuel Arias, Fernando Escuin, Dolores Pérez, Amado Andres, Miguel Angel Martínez and 5 more

Open access · goldAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Antiphospholipid Syndrome and the Kidney.Kidney international reports · 2025
    Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 1 country.

Jose M MoralesHospital 12 de Octubre, Nephrology Department, Healthcare Research Institute (Imas12), Madrid, Spain.
Manuel SerranoHospital 12 de Octubre, Nephrology Department, Healthcare Research Institute (Imas12), Madrid, Spain.
Jose Angel Martinez-FloresHospital 12 de Octubre, Nephrology Department, Healthcare Research Institute (Imas12), Madrid, Spain.
Fracisco Javier GainzaNephrology Department, Hospital Universitario de Cruces, Biocruces Health Research Institute, Baracaldo, Spain.
Roberto MarcenHospital Ramon y Cajal, Nephrology Department, Madrid, Spain.
Manuel AriasHospital Marques de Valdecilla, Nephrology Department, Santander, Spain.
Fernando EscuinHospital la Paz, Nephrology Department, Madrid, Spain.
Dolores PérezHospital 12 de Octubre, Nephrology Department, Healthcare Research Institute (Imas12), Madrid, Spain.
Amado AndresHospital 12 de Octubre, Nephrology Department, Healthcare Research Institute (Imas12), Madrid, Spain.
Miguel Angel MartínezHospital 12 de Octubre, Nephrology Department, Healthcare Research Institute (Imas12), Madrid, Spain.
Naroa MaruriNephrology Department, Hospital Universitario de Cruces, Biocruces Health Research Institute, Baracaldo, Spain.
Eva AlvarezNephrology Department, Hospital Universitario de Cruces, Biocruces Health Research Institute, Baracaldo, Spain.
José Luis CastañerHospital Ramon y Cajal, Nephrology Department, Madrid, Spain.
Marcos López-HoyosHospital Marques de Valdecilla, Nephrology Department, Santander, Spain.
Antonio SerranoHospital 12 de Octubre, Nephrology Department, Healthcare Research Institute (Imas12), Madrid, Spain.
Research Institute Hospital 12 de Octubre · ESBioCruces Health research Institute · ESHospital Universitario Ramón y Cajal · ESMarqués de Valdecilla University Hospital · ESHospital Universitario La Paz · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Graft thrombosis is a devastating complication after renal transplantation. We recently described the association of anti-beta-2-glycoprotein-I (IgA-ab2GP1) antibodies with early graft loss mainly caused by thrombosis in a monocenter study. Methods: Multicenter prospective observational cohort study. Setting and participants: Seven hundred forty patients from five hospitals of the Spanish Forum Renal Group transplanted from 2000 to 2002 were prospectively followed-up for 10 years. Outcomes: Early graft loss and graft loss by thrombosis. Measurements: The presence of IgA anti-B2GP1 antibodies in pretransplant serum was examined using the same methodology in all the patients. Results: At transplantation, 288 patients were positive for IgA-B2GP1 (39%, Group-1) and the remaining were negative (Group-2). Graft loss at 6 months was higher in Group-1 (12.5 vs. 4.2% Limitations: Patients were obtained during a 3-year period (1 January 2000-31 December 2002) and kidneys were only transplanted from brain-dead donors. Nowadays, the patients are older and the percentage of sensitized and retransplants is high. Conclusion: In a prospective observational multicenter study, we were able to corroborate that pretransplant presence of IgA-aB2GP1 was the main risk factor for graft thrombosis and early graft loss. Therefore, a prospective study is needed to evaluate the efficacy and safety of prophylactic anticoagulation to avoid this severe complication.

Indexed as

Kidney Transplantationbeta 2-Glycoprotein ICohort StudiesDelayed Graft FunctionFollow-Up StudiesGraft SurvivalHumansImmunoglobulin AKidneyPredictive Value of TestsPrognosisProspective StudiesRiskSurvival AnalysisThrombosisbeta 2-Glycoprotein IImmunoglobulin Aantiphospholipid antibodiesantiphospholipid syndromeautoantibodiesautoimmunityB2GP1graft thrombosisIgAkidney transplant

Identifiers

PMID29593726
PMCPMC5857545
OpenAlexW2793107153

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.